Highlights
- Telix Pharmaceuticals (ASX:TLX) generated US$245 million in Q3 2026 revenue.
- Precision Medicine quarterly Revenue increased 30% year-on-year to US$201 million.
- Pixclara received US approval for glioma imaging during 2026.
- FY26 revenue guidance remains US$950–970 million, excluding other income.
Telix Pharmaceuticals Limited develops and commercialises diagnostic and therapeutic radiopharmaceuticals for cancer care and operates related Manufacturing services. Its shares (ASX:TLX) traded at AUD 13.20 on November 17, 2026, down 1.42% during the session. Recent company updates describe higher quarterly diagnostic sales, a newly approved brain-cancer imaging product and a proposed transaction to broaden the group’s isotope and therapeutic capabilities.
Precision Medicine and Therapeutics Operations
Telix’s commercial Precision Medicine portfolio includes Illuccix and Gozellix, which are used for prostate-specific membrane antigen positron emission tomography imaging. Its pipeline covers programmes directed at prostate cancer, brain tumours and kidney cancer. Telix Manufacturing Solutions supplies radiopharmacy and related isotope-production infrastructure.
The group operates in a regulated healthcare field where product authorisation, manufacturing quality and reimbursement influence commercial access. Diagnostic product revenue and therapeutic clinical programmes also have different development timelines and spending requirements. For Telix (ASX:TLX), interpreting Earnings therefore requires attention to both marketed products and development activity.
Q3 Commercial and Regulatory Developments
For the quarter ended September 30, 2026, Telix recorded US$245 million in group revenue, up 19% year-on-year and 1% below the immediately preceding quarter. Precision Medicine revenue was US$201 million, up 30% year-on-year. Telix Manufacturing Solutions contributed US$44 million, down from US$47 million in the comparable quarter.
The US Food and Drug Administration approved Pixclara for glioma imaging in September 2026, and the company reported first commercial doses administered that month. Telix (ASX:TLX) also completed enrolment of 350 patients in its BiPASS Phase 3 pre-biopsy prostate cancer imaging study. The regulator granted that programme Fast Track Designation and supported a new drug application pathway.
Clinical Pipeline and Planned ITM Merger
The ProstACT Global Phase 3 therapeutic study continued enrolling outside the United States while Telix prepared an amendment for progression in the US. The company reported that its OPTIMAL-PSMA Phase 2 study had completed enrolment of 120 patients, with a readout expected in the first half of 2027. Further work remains underway in kidney and brain cancer programmes.
Telix announced a proposed Merger with Isotope Technologies Munich, intended to expand its therapeutics pipeline and production capabilities. The transaction includes upfront consideration of US$1.65 billion on a cash-free, debt-free basis and possible contingent consideration of up to US$700 million. It remains subject to Shareholder and customary closing approvals. A shareholder meeting is scheduled for December 1, 2026.
Half-Year Results and FY26 Guidance
For the first half of 2026, Telix reported US$477 million in group revenue, up 22% year-on-year, and a gross Margin of 55%. Adjusted EBITDA reached US$52 million, while Research and Development expenditure was US$124 million. These figures include a US$40 million non-refundable payment associated with its Regeneron collaboration, classified as other income.
Following the third quarter, Telix (ASX:TLX) reiterated FY26 revenue guidance of US$950 million to US$970 million and US$40 million of other income, with combined revenue and other income expected to exceed US$1 billion. FY26 research and development spending guidance was narrowed to US$240 million to US$260 million. The company stated revenue was tracking towards the upper end of the guidance range.
Risks and What to Monitor
Product approvals do not establish future sales levels, and pharmaceutical manufacturing remains subject to inspections, Supply constraints and regulatory compliance. In particular, Telix is addressing third-party manufacturing observations associated with the Zircaix US application. Clinical trial results, reimbursement arrangements, the planned ITM transaction and R&D spending remain distinct sources of uncertainty.
Key Insights
Telix (ASX:TLX) reported higher year-on-year imaging revenue and expanded its approved US diagnostic portfolio during 2026. The next milestones include full-year financial results, clinical readouts, regulatory submissions and a shareholder decision on the proposed ITM merger. Commercial growth and clinical expenditure will need to be assessed together.






Please wait processing your request...